Pattern and related factors of cognitive impairment among chronic methamphetamine users

Wang, Tongyu; Fan, Teng-Teng; Bao, Yanping; Li, Xiaodong; Liang, Chunmei; Wang, Ru-Jia; Ma, Jun; Han, Ying; Meng, Shi-Qiu; Wu, Ping; Shi, Jie; Lü, Lin

doi:10.1111/ajad.12505

Cited by 31 publications

(9 citation statements)

References 31 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Major psychiatric and medical harms related to methamphetamine use include psychosis, agitation, severe anxiety, depression, cardiovascular issues (e.g., arrhythmias, myocardial infarction, and cerebrovascular accidents), infectious diseases (e.g., HIV and hepatitis), and dental problems, all of which require interventions within various health settings. [6][7][8][9][10][11][12][13][14] Primary care, EDs, and other health services settings all need to maximize their ability to respond to these complex sequelae. 106 Even health services for pregnant women may need to increase their attention to the use of methamphetamine.…”

Section: How Do Community and Health System Responses To Resurgent Me...mentioning

confidence: 99%

“…doi: 10.1111/nyas.14688 logic deficits, cardiovascular and renal dysfunction, transmission of HIV, viral hepatitis, and sexually transmitted infections, overdose, and increased mortality. [6][7][8][9][10][11][12][13][14] Drug overdose death rates involving psychostimulants increased more than 300%, from 1.2 per 100,000 in 2013 to 5.0 per 100,000 in 2019. 3 During this same period, the percentage of overdose deaths involving psychostimulants rose from 8.2% in 2013 to 22.9% in 2019, becoming the second most numerous drug class involved in overdose deaths in 2019 (after opioids as a class).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction

Jones

Houry

Han

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Recent attention has focused on the growing role of psychostimulants, such as methamphetamine in overdose deaths. Methamphetamine is an addictive and potent stimulant, and its use is associated with a range of physical and mental health harms, overdose, and mortality. Adding to the complexity of this resurgent methamphetamine threat is the reality that the increases in methamphetamine availability and harms are occurring in the midst of and intertwined with the ongoing opioid overdose crisis. Opioid involvement in psychostimulant-involved overdose deaths increased from 34.5% of overdose deaths in 2010 to 53.5% in 2019-an increase of more than 50%. This latest evolution of the nation's overdose epidemic poses novel challenges for prevention, treatment, and harm reduction. This narrative review synthesizes what is known about changing patterns of methamphetamine use with and without opioids in the United States, other characteristics associated with methamphetamine use, the contributions of the changing illicit drug supply to use patterns and overdose risk, motivations for couse of methamphetamine and opioids, and awareness of exposure to opioids via the illicit methamphetamine supply. Finally, the review summarizes illustrative community and health system strategies and research opportunities to advance prevention, treatment, and harm reduction policies, programs, and practices.

show abstract

Section: How Do Community and Health System Responses To Resurgent Me...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction

Jones

Houry

Han

et al. 2021

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…The phenomenon of increasing methamphetamine use among people using opioids is of great concern. Methamphetamine use carries its own risks, including a range of physical and mental health consequences such as psychosis and other mental disorders, cognitive and neurological deficits, cardiovascular and renal dysfunction, transmission of HIV, viral hepatitis and sexually transmitted infections and increased mortality . Individuals who use both opioids and methamphetamine are more likely to be homeless, inject drugs daily or more than once a day, reuse or share syringes and report a non‐fatal overdose in the past year compared to people who inject either drug alone .…”

Section: Introductionmentioning

confidence: 99%

Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17

2019

View full text Add to dashboard Cite

Background and Aims Due to their small sample sizes, geographic specificity and limited examination of socio-demographic characteristics, recent studies of methamphetamine use among people using heroin in the United States are limited in their ability to identify national and regional trends and to characterize populations at risk for using heroin and methamphetamine. This study aimed to examine trends and correlates of methamphetamine use among heroin treatment admissions in the United States. Design Longitudinal analysis of data from the 2008 to 2017 Treatment Episode Data Set.Descriptive statistics, trend analyses and multivariable logistic regression were used to examine characteristics associated with methamphetamine use among heroin treatment admissions. Setting United States. Participants Treatment admissions of people aged ≥ 12 years whose primary substance of use is heroin. Measurements Primary measurement was heroin treatment admissions involving methamphetamine. Secondary measurements were demographics of sex, age, race/ethnicity, US census region, living arrangement and employment status. Findings The percentage of primary heroin treatment admissions reporting methamphetamine use increased each year from 2.1% in 2008 to 12.4% in 2017, a relative percentage increase of 490% and an annual percentage change (APC) of 23.4% (P < 0.001). During the study period, increases were seen among males and females and among all demographic and geographic groups examined. Among primary heroin treatment admissions reporting methamphetamine use in 2017, 47.1% reported injecting, 46.0% reported smoking, 5.1% reporting snorting and 1.8% reported oral/other as their usual route of methamphetamine use. Conclusions Methamphetamine use among heroin treatment admissions in the United States increased from one in 50 primary heroin treatment admissions in 2008 to one in 8 admissions in 2017.

show abstract

“…METH have not only neurotoxic [71] but also neuroprotective effects [72] when low doses of METH were administered within 12 h after severe traumatic brain injury (TBI) in rodents, which elucidates its therapeutic potential [73]. In chronic METH users, CDs occurred frequently as measured by Montreal Cognitive Assessment (MoCA) [74] especially in concentration and memory [75]. A meta-analysis revealed impairment in most cognitive domains [76].…”

Section: Methamphetamine (Meth)mentioning

confidence: 99%

Mechanism of psychoactive substance-induced cognitive disorders: does tau protein play a role?

Wang¹,

Lv²,

He³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Psychoactive substances are a class of chemical substances which could cause public health threats. Cognitive disorders are a category of mental health disorders that primarily affect cognitive abilities. Tau protein could maintain neuronal cytoskeleton stabilization. Post-translational modification of tau, especially phosphorylation, is an important way to regulate the structure and function of tau and phosphorylated tau is closely related to cognitive function. Lots of studies have reported the phenomenon that psychoactive substances can cause cognitive function impairment. We reviewed recent related studies and discussed them by drug classification. We mainly focused on cognitive disorders caused by acute or chronic exposure of each drugs, animal experiments and the mechanisms associated with tau phosphorylation, then compared the similarities and differences among them, trying to find out the common rules. The results suggested that tau phosphorylation is involved in psychoactive substance-induced cognitive disorder and different psychoactive substances may act by affecting amount or activity of different kinases and phosphatases in the metabolic pathway of tau. We demonstrated that tau protein is a potential target for psychoactive substances induced cognitive disorder treatments.

show abstract

Pattern and related factors of cognitive impairment among chronic methamphetamine users

Cited by 31 publications

References 31 publications

Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction

Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction

Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17

Mechanism of psychoactive substance-induced cognitive disorders: does tau protein play a role?

Contact Info

Product

Resources

About